List of Excipients in Branded Drug BIMATOPROST

Generic Drugs Containing BIMATOPROST

Company	Ingredient	NDC	Excipient
Sandoz Inc	bimatoprost	0781-6206	BENZALKONIUM CHLORIDE
Sandoz Inc	bimatoprost	0781-6206	CITRIC ACID MONOHYDRATE
Sandoz Inc	bimatoprost	0781-6206	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in BIMATOPROST?

# Of NDCs	Excipient
20	BENZALKONIUM CHLORIDE
2	BORIC ACID
18	CITRIC ACID MONOHYDRATE

Bimatoprost Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 16, 2026

Bimatoprost is a mature ophthalmic active with limited composition-of-matter exclusivity but continuing commercial opportunity in preservative-free formulations, multidose delivery systems, sustained-release implants, combination products, and differentiated products for eyelash hypotrichosis. The main excipient issue is benzalkonium chloride, which supports multidose microbiological protection but can worsen ocular-surface tolerability with chronic use. FDA-approved bimatoprost products include ophthalmic solutions for glaucoma or ocular hypertension, LATISSE for eyelash hypotrichosis, and DURYSTA, a biodegradable intracameral implant.[1-4]

What is the commercial status of bimatoprost?

Bimatoprost is a prostamide analogue used to reduce elevated intraocular pressure and, at a different commercial positioning, increase eyelash prominence. The principal reference products are:

Product	Active ingredient	Strength	Dosage form	FDA indication	Reference company
LUMIGAN	Bimatoprost	0.01% and historically 0.03%	Topical ophthalmic solution	Glaucoma and ocular hypertension	Allergan, now AbbVie
LATISSE	Bimatoprost	0.03%	Topical solution	Hypotrichosis of the eyelashes	Allergan, now AbbVie
DURYSTA	Bimatoprost	10 mcg implant	Intracameral biodegradable implant	Reduction of intraocular pressure	Allergan, now AbbVie
Generic bimatoprost ophthalmic solution	Bimatoprost	Generally 0.01% or 0.03%	Topical ophthalmic solution	Primarily glaucoma and ocular hypertension	Multiple manufacturers

LUMIGAN 0.01% uses a low-concentration formulation designed for once-daily topical administration. LATISSE uses a disposable applicator system and is applied to the upper eyelid margin. DURYSTA uses a biodegradable implant delivered into the anterior chamber by an ophthalmic applicator.[1-3]

The commercial market is divided between low-cost generic topical solutions and higher-value differentiated products. Generic topical bimatoprost faces price competition. Preservative-free products, combination therapies, delivery devices, and sustained-release products have greater potential to preserve margins.

What excipients are used in bimatoprost ophthalmic solutions?

The core excipient system for conventional bimatoprost ophthalmic solution includes a preservative, tonicity agent, buffer, pH adjusters, and purified water. The LUMIGAN 0.01% label identifies benzalkonium chloride as the preservative and includes sodium chloride, sodium phosphate dibasic, citric acid, hydrochloric acid and sodium hydroxide for pH adjustment, with purified water as the vehicle.[1]

Excipient function	Common ingredient in bimatoprost solution	Commercial purpose
Preservative	Benzalkonium chloride	Controls microbial contamination in multidose packaging
Tonicity adjustment	Sodium chloride	Improves ocular comfort and osmotic compatibility
Buffering	Sodium phosphate dibasic and citric acid	Maintains formulation pH and chemical stability
pH adjustment	Hydrochloric acid and sodium hydroxide	Controls final pH
Vehicle	Purified water	Solubilizes and delivers the active ingredient

The excipient system is relatively conventional. The main formulation opportunity is therefore not a new excipient combination alone. It is the integration of excipient selection with container closure, preservative strategy, delivery frequency, ocular-surface tolerability, and stability.

Why is benzalkonium chloride important in bimatoprost products?

Benzalkonium chloride, or BAK, enables multidose packaging but is associated with ocular-surface irritation, tear-film disruption, conjunctival inflammation, and epithelial toxicity, particularly with chronic exposure. These risks matter because glaucoma treatment is often lifelong and patients may use several preserved ophthalmic products simultaneously.

BAK concentration is a potential differentiation variable. A lower BAK concentration may improve tolerability, but the product must still meet preservative effectiveness, sterility, container-closure, and in-use stability requirements. Reducing BAK without validating microbial protection creates regulatory and commercial risk.

Key development strategies include:

1. A BAK-free single-dose product.
2. A BAK-free multidose bottle using a validated preservative-free valve or airless system.
3. A reduced-BAK formulation supported by comparative ocular-surface data.
4. A formulation using an alternative preservative, subject to compatibility and tolerability testing.
5. A unit-dose product for patients with severe ocular-surface disease or preservative intolerance.

A preservative-free product can command a premium over standard generic bimatoprost, but packaging costs, filling complexity, dose wastage, and reimbursement constraints can reduce the net margin advantage.

What formulations are protected by bimatoprost patents?

The original bimatoprost composition-of-matter and formulation patent estate is substantially mature. Core patents associated with bimatoprost and prostamide analogues were filed in the 1990s and have generally reached expiration or passed through the principal U.S. patent term. Commercial risk now centers on later patents covering formulations, devices, manufacturing processes, combinations, or sustained-release systems.

The relevant patent categories are:

Patent category	Relevance to bimatoprost	Current commercial significance
Composition of matter	Protects bimatoprost or related prostamide compounds	Primarily historical
Topical formulation	Covers concentration, pH, excipient ratios, or stability	Potentially relevant for branded or differentiated products
Preservative-free packaging	Covers bottle, valve, closure, or unit-dose delivery	Important for generic and specialty entrants
Method of use	Covers treatment of glaucoma, ocular hypertension, or eyelash hypotrichosis	Limited where indication patents have expired
Combination therapy	Covers bimatoprost with timolol or other ophthalmic agents	Relevant to fixed-dose products
Sustained release	Covers biodegradable implants, inserts, or depot formulations	Highest strategic value
Manufacturing process	Covers crystallization, purification, particle control, or sterile processing	Can raise technical barriers even where product patents are weak

A definitive freedom-to-operate assessment requires a live review of issued claims, terminal disclaimers, continuations, international equivalents, and litigation history. The public commercial record supports the conclusion that conventional bimatoprost solution is a low-barrier generic category, while implant and device-enabled products have stronger potential patent protection.

When does bimatoprost lose exclusivity?

The principal U.S. exclusivity period for topical bimatoprost products has expired. Generic bimatoprost ophthalmic solutions are marketed, and FDA records show that the product category is no longer protected by the original branded exclusivity framework.[5]

The main exclusivity milestones are:

Milestone	Commercial implication
Original bimatoprost patents	Historical barrier to generic entry
LUMIGAN approval	Established glaucoma and ocular-hypertension market
LATISSE approval in 2008	Created a separate eyelash-hypotrichosis market
Generic ophthalmic solution approvals	Reduced price and increased channel competition
DURYSTA approval in 2020	Repositioned bimatoprost as a sustained-release delivery platform
DURYSTA supplementary approvals and patents	May support later-stage differentiation around implant use and delivery

DURYSTA has a separate product-specific regulatory and patent profile from topical bimatoprost solution. The implant’s market protection depends on the combination of regulatory exclusivity, device claims, implant composition, delivery apparatus, manufacturing methods, and any listed patents.

What is the Orange Book status of bimatoprost?

The FDA Orange Book lists approved drug products and, where applicable, patents and exclusivity information. Conventional bimatoprost ophthalmic solutions are represented by multiple abbreviated new drug applications. The existence of generic approvals indicates that the core topical product is open to abbreviated approval pathways.[5]

Orange Book analysis should distinguish:

• LUMIGAN ophthalmic solution;
• LATISSE ophthalmic solution;
• DURYSTA intracameral implant;
• bimatoprost-timolol fixed-dose combinations;
• dosage strength and route;
• active patent listings versus expired patents;
• product-specific exclusivity versus older compound patents.

A Paragraph IV challenge to an active listed patent can trigger a 30-month stay under the Hatch-Waxman framework if the reference sponsor files timely infringement litigation.[6] For mature topical bimatoprost solutions, the practical risk is less likely to involve the original active-ingredient patent and more likely to involve a later formulation, packaging, or method-of-use patent.

Which companies are challenging bimatoprost exclusivity?

Generic ophthalmic manufacturers have entered the bimatoprost solution market through ANDAs. The competitive set has included large generic companies and ophthalmic specialists, with market participation varying by strength, supplier contracts, and reimbursement channel.

The main competitive groups are:

• Large generic manufacturers supplying retail and institutional channels.
• Ophthalmic-focused companies selling preservative-free or specialty products.
• Branded companies using fixed-dose combinations.
• Device companies developing sustained-release delivery systems.
• Compounding pharmacies, which may affect limited segments but do not provide the same regulatory substitution status as FDA-approved generics.

The most commercially significant challenge to a branded bimatoprost product is usually an ANDA for the same strength and route. A more disruptive competitor would combine bimatoprost with preservative-free packaging, lower dosing frequency, or a fixed-dose adjunctive agent.

How does DURYSTA compare with topical bimatoprost?

DURYSTA changes the commercial value proposition by replacing daily topical administration with a biodegradable intracameral implant. Its FDA-approved formulation contains bimatoprost in a biodegradable implant matrix. The product label identifies poly(DL-lactide-co-glycolide) and magnesium stearate among the inactive ingredients.[3]

Attribute	Topical bimatoprost solution	DURYSTA
Administration	Patient-administered daily	Physician-administered intracamerally
Preservative exposure	May include BAK	No topical multidose preservative burden
Adherence risk	High over long treatment periods	Reduced daily adherence burden
Manufacturing complexity	Moderate sterile ophthalmic filling	High implant fabrication and applicator control
Reimbursement	Pharmacy or medical benefit depending on product	Primarily procedure-linked medical benefit
Main commercial risk	Generic price erosion	Procedure adoption, safety, reimbursement, retreatment limits
Patent value	Mostly mature product category	Higher potential around implant and delivery technology

DURYSTA is commercially attractive because it creates a platform around controlled release rather than a commodity eye drop. Its constraints include physician training, administration requirements, intraocular safety considerations, reimbursement, and the regulatory burden of a drug-device delivery system.

What excipient opportunities exist for preservative-free bimatoprost?

The strongest near-term excipient opportunity is a preservative-free product that maintains chemical stability and sterility through packaging rather than antimicrobial excipients.

Potential approaches include:

Unit-dose preservative-free ampoules

Unit-dose packaging removes the need for a multidose preservative. It is technically straightforward but can increase packaging waste, manufacturing cost, and patient handling complexity.

Preservative-free multidose bottles

Airless pumps, one-way valves, filters, and mechanically protected dispensing systems can reduce contamination risk. The intellectual-property opportunity may reside more in the container closure and fluid path than in the bimatoprost composition.

Low-surfactant or surfactant-free systems

Excipients that improve wetting or solubilization can affect comfort, extractables, adsorption, and preservative performance. Any surfactant change requires compatibility testing with the bottle and dropper tip.

Mucoadhesive systems

Polymers that extend residence time on the ocular surface could support lower dosing frequency. The tradeoff is blurred vision, discharge, altered drug release, and potential patient rejection.

In situ gels

Thermosensitive or ion-responsive gels can prolong retention after instillation. These systems face viscosity, drop-size, device compatibility, and patient-comfort constraints.

Nanodispersions and lipid systems

Lipid-based carriers may improve residence time or reduce dose volume. They can also introduce particle-size, sterilization, physical stability, and scale-up challenges.

What commercial opportunities exist in bimatoprost combination products?

Fixed-dose combinations can defend value by improving adherence and reducing bottle burden. Bimatoprost-timolol products are the clearest commercial example. Additional combinations could target patients requiring multiple pressure-lowering mechanisms, but each combination must demonstrate adequate stability, compatibility, dosing rationale, and regulatory comparability.

Potential combination opportunities include:

• Bimatoprost with timolol.
• Bimatoprost with a carbonic anhydrase inhibitor.
• Bimatoprost with an alpha agonist.
• Bimatoprost in a preservative-free fixed-dose product.
• Bimatoprost with digital adherence monitoring or smart dispensing.

The main risk is substitution by established branded or generic combination products. A new combination needs a measurable advantage in dosing frequency, tolerability, adherence, or total treatment cost.

What patent litigation affects bimatoprost?

The major historical disputes around bimatoprost involved originator patents, generic entry, and formulation protection. The present risk profile is more fragmented. Potential litigation areas include:

• ANDA Paragraph IV challenges;
• infringement claims involving formulation concentrations;
• preservative-free delivery systems;
• fixed-dose combinations;
• intracameral implants;
• applicators and implant delivery devices;
• manufacturing and purification processes.

A topical generic entrant should evaluate patent claims covering the exact strength, excipient ranges, container closure, labeling, and proposed indication. A sustained-release entrant must also review implant geometry, polymer composition, degradation profile, drug loading, delivery tools, and retreatment methods.

How strong is the bimatoprost patent estate?

The estate is weak for undifferentiated topical solution and stronger for delivery technology.

Segment	Patent strength	Entry barrier
Standard 0.01% solution	Low to moderate	Generic formulation and regulatory equivalence
Standard 0.03% solution	Low to moderate	Generic manufacturing and market access
Preservative-free solution	Moderate	Packaging, sterility, stability, and device patents
Fixed-dose combination	Moderate	Formulation, clinical, and patent differentiation
Eyelash-hypotrichosis product	Moderate	Labeling, trademark, distribution, and indication strategy
Biodegradable implant	Moderate to high	Drug-device manufacturing, clinical evidence, delivery system
New sustained-release depot	High if claims are narrow and technically difficult	Clinical development and manufacturing scale-up

Patent strength depends on claim breadth, validity under obviousness standards, enablement, written description, prosecution history, and the availability of non-infringing formulation alternatives. Excipients alone rarely create durable protection unless they produce an unexpected stability, tolerability, release, or manufacturing result.

What generic launch risks exist for bimatoprost?

A generic launch faces several risks despite the maturity of the active ingredient:

1. Price erosion. Multiple ANDA sponsors can rapidly reduce reimbursement and wholesaler margins.
2. Formulation equivalence. Differences in pH, osmolality, viscosity, preservative level, or drop size can affect regulatory comparability.
3. Container-closure performance. Preservative-free products require robust microbial ingress and in-use stability data.
4. Supply reliability. Sterile ophthalmic manufacturing has high failure costs and limited qualified capacity.
5. Indication carve-outs. A generic label may omit protected indications while retaining unprotected uses.
6. Device dependence. Specialty products may require proprietary applicators or administration systems.
7. Litigation timing. A Paragraph IV launch can trigger an infringement action and a potential 30-month stay.[6]

The lowest-risk entry is a conventional solution with established excipients and a standard bottle. The highest-value opportunity is a preservative-free or sustained-release product, but it carries greater development and regulatory risk.

What licensing deals could create value in bimatoprost?

Licensing opportunities are most credible in three areas:

• Preservative-free multidose packaging.
• Biodegradable ocular implants or inserts.
• Fixed-dose or sustained-release combinations.

A bimatoprost license can be structured around an active pharmaceutical ingredient, formulation patent, container-closure technology, implant platform, regional commercialization rights, or manufacturing know-how. The asset should be valued against generic price erosion, development cost, clinical differentiation, and the remaining patent term.

For a specialty-pharma buyer, the most attractive target is a validated delivery platform with data in glaucoma patients and a clear regulatory route. For a generic company, the priority is a low-cost preservative-free product with reliable sterile manufacturing and a defensible device configuration.

What FDA regulatory pathway applies to new bimatoprost products?

A conventional product equivalent to an approved topical solution can generally use the ANDA pathway, subject to active ingredient, strength, dosage form, route, bioequivalence, labeling, and manufacturing requirements.[6]

A materially different product may require a 505(b)(2) application. This pathway is relevant to:

• New preservative-free formulations;
• altered dosing frequency;
• new delivery devices;
• sustained-release ocular systems;
• new combinations;
• new strengths or routes;
• reformulations relying partly on FDA findings for an approved product.

DURYSTA demonstrates the higher regulatory burden associated with a biodegradable intracameral implant. The product required clinical evaluation of intraocular safety, delivery, duration of effect, and retreatment considerations in addition to conventional drug quality requirements.[3]

Key Takeaways

• Bimatoprost topical solution is a mature, genericized market with limited value in undifferentiated excipient substitution.
• Benzalkonium chloride is the central excipient and commercial risk because it supports multidose preservation but can impair chronic ocular-surface tolerability.
• Preservative-free unit-dose and multidose systems offer the clearest formulation opportunity.
• Packaging, sterile manufacturing, and delivery-device claims may provide stronger protection than new excipient combinations.
• Fixed-dose combinations can improve adherence but face established generic competition.
• DURYSTA demonstrates the higher-value opportunity in biodegradable sustained-release delivery.
• Conventional topical products are generally suited to the ANDA pathway, while innovative delivery systems may require 505(b)(2) or a more extensive development program.
• Generic launch risk is highest from price erosion, formulation equivalence requirements, sterile supply constraints, and Paragraph IV litigation.
• The bimatoprost patent estate is comparatively weak for standard solutions and stronger for implants, devices, and technically differentiated delivery systems.

FAQs

Is bimatoprost preservative-free?

Most conventional multidose bimatoprost ophthalmic solutions use benzalkonium chloride. Preservative-free versions may use unit-dose packaging or specialized multidose containers.

Can bimatoprost be reformulated with a different preservative?

Yes, but the new product must demonstrate microbial protection, chemical stability, ocular tolerability, container compatibility, and regulatory equivalence or clinical suitability.

Is DURYSTA a generic version of bimatoprost eye drops?

No. DURYSTA is a separate intracameral biodegradable implant product. It uses the same active ingredient but has a distinct dosage form, administration method, manufacturing process, safety profile, and regulatory pathway.

Does bimatoprost have biosimilar risk?

No. Bimatoprost is a chemically synthesized small molecule, not a biologic. The relevant competitors are generics, follow-on formulations, combination products, and delivery systems rather than biosimilars.

What is the highest-value bimatoprost development strategy?

The strongest commercial strategies are preservative-free chronic-use products, fixed-dose combinations with adherence benefits, and sustained-release delivery systems that reduce daily dosing and limit exposure to topical preservatives.

References

1. U.S. Food and Drug Administration. (2023). LUMIGAN (bimatoprost ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2023). LATISSE (bimatoprost ophthalmic solution) prescribing information.
3. U.S. Food and Drug Administration. (2023). DURYSTA (bimatoprost implant) prescribing information.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process and Paragraph IV certifications.